Diammonium Glycyrrhizinate Attenuates Aβ_1–42‐Induced Neuroinflammation and Regulates MAPK and NF‐κB Pathways <i>In Vitro</i> and <i>In Vivo</i>

Abstract

DG protects Aβ(1-42) -induced AD models in vitro and in vivo through reducing activation of microglia and inflammation, which may be involved in MAPK and NF-κB pathways.